|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
|
|---|---|---|
| Revenue | ||
| Operating expenses: | ||
| Research and development | ||
| General and administrative | ||
| Gain on sale of non-financial asset | ||
| Total operating expenses | ||
| Loss from operations | ||
| Other income, net: | ||
| Interest income | ||
| Other expense, net | ||
| Total other income, net | ||
| Loss before provision (benefit) for income taxes | ||
| Provision (benefit) for income taxes | ||
| Net loss | ||
| Net (loss) income applicable to common stockholders | ||
| Net unrealized gain on marketable securities | ||
| Total other comprehensive income | ||
| Comprehensive loss | ||
| Net (loss) income per share attributable to common stockholders: | ||
| Net loss per share, basic | ||
| Net loss per share, diluted | ||
| Weighted-average shares outstanding used in computing net (loss) income per share attributable to common stockholders: | ||
| Weighted-average shares outstanding, basic | ||
| Weighted-average shares outstanding, diluted |
Loading...
